AIxCrypto Holdings, Inc. (AIXC) Stock Ticker
AIXC right now
Market factors today
Unlock the full AIXC picture
About AIxCrypto Holdings, Inc.
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
AIXC stock facts
| Ticker symbol | AIXC |
| Exchange | NASDAQ Capital Market |
| Sector | Technology |
| Industry | Software - Infrastructure |
| Market cap | $35.0M |
| CEO | Jiawei Wang |
| Employees | 10 |
| Headquarters | El Segundo, CA, US |
| IPO date | 2015-06-23 |
| Website | www.aixcrypto.ai |
What you can see for AIXC on Tickr
Live AIXC price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AIXC report.
Rankings
FAQ
What is the ticker symbol for AIxCrypto Holdings, Inc.?
The ticker symbol for AIxCrypto Holdings, Inc. is AIXC, listed on the NASDAQ Capital Market.
What is AIXC?
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid…